An individual-participant meta-analysis of prospective studies revealed menopausal hormone therapy associated with an elevation in the risk of breast cancer, with the highest risks associated with daily combined therapy.
Administering trastuzumab after a course of anthracycline therapy for breast cancer can result in cardiac toxicity. Serial echocardiograms in this study showed that a lower initial left ventricular ejection fraction before anthracycline therapy and the amount of decrease in ejection fraction after the anthracycline course are predictive of subsequent trastuzumab cardiac toxicity.
In a pooled analysis of prospective studies, researchers found an increased risk of breast cancer among parous women that persists for more than 20 years after childbirth. Breastfeeding did not modify this pattern.
Large study includes all forms of current hormonal contraception
December 28, 2017
Results from a study of 1.8 million Danish women ages 15-49 indicate that the risk of breast cancer is increased among women who currently or recently used contemporary hormonal contraceptives compared to those women who have never used such methods. While the risk increased with longer use, the absolute increases in risk were small.
Using data from the Two Sister Study, investigators found no association of past combined hormone replacement therapy with young-onset (before age 50) breast cancer, and a protective effect with estrogen-only therapy.